EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer

Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 258 (2012).

Lung cancer for adults. NICE quality standard 17 (2012).

Erlotinib monotherapy for the maintenance treatment of non-small-cell lung cancer. NICE technology appraisal guidance 227 (2011).

Lung cancer: the diagnosis and treatment of lung cancer. NICE clinical guideline 121 (2011).

Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 192 (2010).

Pemetrexed for the maintenance treatment of non-small-cell lung cancer. NICE technology appraisal guidance 190 (2010).

Pemetrexed for the first-line treatment of non-small-cell lung cancer. NICE technology appraisal guidance 181(2009).

Erlotinib for the treatment of non-small-cell lung cancer. NICE technology appraisal guidance 162 (2008).

Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses. NICE interventional procedure guidance 254 (2008).

Pemetrexed for the treatment of non-small-cell lung cancer. NICE technology appraisal guidance 124 (2007).